Pain Care Legislation & Policy Update

On June 17, 2020, DCBA Law & Policy Managing Partner Michael Barnes presented alongside Wade Delk, Government Affairs Director of the American Society for Pain Management Nursing (ASPMN), for the Providers Clinical Support System (PCSS) 2020 Pain Care Legislation and Public Policy Webinar. Mr. Barnes and Mr. Delk provided an update on state and federal […]

DEA Temporarily Relaxes Telemedicine Standards for Prescribing Buprenorphine During COVID-19 Outbreak

The Drug Enforcement Administration (DEA) has temporarily relaxed the federal requirements for prescribing buprenorphine for opioid use disorder (OUD) via telemedicine during the COVID-19 public health emergency. As a general rule, the federal Controlled Substances Act (CSA) requires a valid prescription before a controlled prescription medication may be delivered, distributed, or dispensed by means of […]

FORE Issues Opinion Letter on Prescribing Buprenorphine with Telemedicine During COVID-19 Outbreak

The COVID-19 outbreak has presented extraordinary challenges in prescribing buprenorphine to new and existing patients with opioid use disorder (OUD). Telemedicine presents an opportunity to reach these patients and promote continuity of care; however, rapidly evolving circumstances have caused confusion among many practitioners as to their rights and obligations under federal law when prescribing controlled […]

DCBA Attorneys to Present and Moderate at 2020 Rx Summit

Four DCBA Law & Policy attorneys have been selected to speak or moderate at the Rx Drug Abuse & Heroin Summit in Nashville next month. DCBA will also exhibit at the conference. Partner Stacey Worthy will join two nationally renowned addiction physicians in presenting, ‚ÄúDuking It Out Over Electronic Data-Sharing: Law, Ethics, and Best Practices […]

DEA Issues Proposed Rule to Expand Access to Mobile Opioid Treatment

On February 26, 2020, DEA issued a proposed rule titled Registration Requirements for Narcotic Treatment Programs with Mobile Components. The proposed rule would waive the requirement of a separate registration for opioid treatment programs (OTPs) that utilize a mobile component. The Controlled Substances Act (CSA) generally requires, with certain exceptions, all persons who dispense controlled […]